Clinical Trial Update: Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 safety study of FG-3019 (fresolimumab) in incipient diabetic nephropathy due to type 1 or type 2 diabetes has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• FG-3019 (fresolimumab)

Snippet

Sponsor: Kyntra Bio | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED